. "Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood . 2026;147(18):2041-2052.." Blood, 2026. doi:10.1182/blood.2026034829